The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
Van K. Morris
Consulting or Advisory Role - Incyte; Regeneron
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Novartis (Inst); Pfizer (Inst)
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
Shannon L. Puhalla
Consulting or Advisory Role - Abbvie; AstraZeneca; Celldex; Eisai; Pfizer; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Covance/Bayer (Inst); Incyte (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - Patent No PCT/US2022/021720, "Small molecules and their use as MALT1 inhibitors"
Atif Iqbal
No Relationships to Disclose
Patrick M Boland
Consulting or Advisory Role - Bayer; Guardant Health; Merck; Pfizer; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); Compass Therapeutics (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
Dustin A. Deming
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Seagen
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
Aaron J. Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
Howard J Lim
Honoraria - Amgen; Astellas Pharma; AstraZeneca Canada; BMS Canada; Dicephera Pharmaceuticals, Inc.; eisai; Ipsen; Merck; Roche Canada; Taiho Pharmaceutical; Varian Medical Systems
Research Funding - Roche (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Taiho Oncology
Samuel A. Jacobs
Employment - Exact Sciences
Consulting or Advisory Role - Exact Sciences
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; NextCure; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
Norman Wolmark
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck Sharp & Dohme LLC (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Komen
Thomas J. George
Consulting or Advisory Role - BillionToOne; Seagen; Tempus
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)